ProQR Therapeutics N.V. - Ordinary Shares (PRQR) News

ProQR Therapeutics N.V. - Ordinary Shares (PRQR): $5.33

0.23 (+4.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRQR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter PRQR News Items

PRQR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRQR News Highlights

  • PRQR's 30 day story count now stands at 2.
  • Over the past 5 days, the trend for PRQR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • RNA, EYE and RARE are the most mentioned tickers in articles about PRQR.

Latest PRQR News From Around the Web

Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.

ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last vis

Yahoo | January 4, 2022

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (“Kreos”) and Pontifax Medison Debt Financing (“Pontifax”). The amended agreement provides ProQR with access to up to an additional $90 million

Yahoo | December 30, 2021

Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now?

ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $7.43. Actively observing the price movement in the last trading, the stock closed the session at $7.00, falling within a range of $6.75 Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now? Read More »

Stocks Register | December 18, 2021

ProQR (PRQR) Gets a Buy Rating from JMP Securities

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on ProQR (PRQR – Research Report) today and set a price target of $31.00. The company's shares closed last Thursday at $7.00. According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 28.6% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $23.80.

Catie Powers on TipRanks | December 16, 2021

ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.

Intrado Digital Media | December 16, 2021

ProQR Therapeutics N.V. (PRQR) Probability Sentiment

Proqr Therapeutics N.v. (NASDAQ:PRQR) Probability Sentiment SUMMARY In many diseases, discovering the key gene or protein target to treat remains elusive. Not so with the rare eye disease CEP290-mediated Leber congenital amaurosis (LCA10). People with CEP290-mediated LCA10 suffer vision loss because of a specific mutation in the CEP290 gene. The []

GEO Investing | December 11, 2021

Northern Trust Corp Has $91,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR)

Northern Trust Corp lowered its position in shares of ProQR Therapeutics (NASDAQ:PRQR) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,481 shares of the biopharmaceutical companys stock after selling 4,432 shares during the quarter. Northern Trust Corps holdings in []

Dakota Financial News | December 7, 2021

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of Buy by Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average rating of Buy by the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages []

Dakota Financial News | November 30, 2021

ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Fifty Day Moving Average of $7.86

Shares of ProQR Therapeutics (NASDAQ:PRQR) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $7.86 and traded as low as $7.41. ProQR Therapeutics shares last traded at $7.50, with a volume of 301,156 shares. A number of brokerages have issued reports on PRQR. []

Transcript Daily | November 24, 2021

ProQR Announces Highlights from Analyst Event

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Companys clinical-stage programs and RNA editing technology platforms.

Intrado Digital Media | November 18, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6535 seconds.